Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N. Graf RP, et al. Among authors: fisher v. JAMA Netw Open. 2022 Mar 1;5(3):e225394. doi: 10.1001/jamanetworkopen.2022.5394. JAMA Netw Open. 2022. PMID: 35357449 Free PMC article.
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, Minker M, Li G, Fisher V, Sokol ES, Pavlick DC, Moore JA, Braly A, Singal G, Fabrizio D, Comment LA, Rizvi NA, Alexander BM, Frampton GM, Hegde PS, Albacker LA. Montesion M, et al. Among authors: fisher v. Cancer Discov. 2021 Feb;11(2):282-292. doi: 10.1158/2159-8290.CD-20-0672. Epub 2020 Oct 30. Cancer Discov. 2021. PMID: 33127846
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ. Graf RP, et al. Among authors: fisher v. Eur Urol. 2022 Jan;81(1):37-47. doi: 10.1016/j.eururo.2021.09.030. Epub 2021 Oct 26. Eur Urol. 2022. PMID: 34716049 Free article.
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N. Swami U, et al. Among authors: fisher v. Clin Cancer Res. 2022 Nov 14;28(22):4917-4925. doi: 10.1158/1078-0432.CCR-22-2228. Clin Cancer Res. 2022. PMID: 36088616
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF, Graf RP, Fisher VA, Oxnard GR, Ellis H, Panarelli N, Lin DI, Li G, Huang RSP, Ross JS, Myer PA, Klempner SJ. Quintanilha JCF, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2252244. doi: 10.1001/jamanetworkopen.2022.52244. JAMA Netw Open. 2023. PMID: 36689222 Free PMC article.
Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice.
Schröder C, Gower-Page C, Reyes-Rivera I, Patel A, Price R, Sen S, Davies J, Castellanos E, Snider J, Bai X, Fisher V, Mhatre SK. Schröder C, et al. Among authors: fisher v. JCO Clin Cancer Inform. 2022 Mar;6:e2100133. doi: 10.1200/CCI.21.00133. JCO Clin Cancer Inform. 2022. PMID: 35297649 Free PMC article.
139 results